Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica SPA is a pharmaceutical company headquartered in Milan, Italy. It was founded in 1926 by Giovanni Recordati and has since grown into a leading international pharmaceutical company. The company specializes in developing and manufacturing prescription drugs, primarily in the cardiovascular and urogenital therapeutic areas. It also has a strong presence in the fields of neurology, psychiatry, and pediatric medicine. Recordati has research and development facilities in Italy, France, and Spain, and a commercial presence in over 130 countries worldwide. The company’s mission is to improve patient’s quality of life through innovative and effective treatments.

1. Long history and experience: Recordati Industria Chimica e Farmaceutica SPA was founded in 1926 and has been in the pharmaceutical industry for over 90 years. This demonstrates the company's stability and expertise in the sector.
2. Strong international presence: The company has a global presence, with subsidiaries and offices in over 130 countries worldwide.
3. Focus on research and development: Recordati invests a significant portion of its revenue into research and development, constantly seeking innovative solutions to healthcare challenges.
4. Diverse product portfolio: The company has a wide range of products in various therapeutic areas, including cardiovascular, urological, neurochemical, and psychiatric disorders. This diversity ensures a steady revenue stream and reduces dependence on any single product.
5. Commitment to quality: Recordati has a strict quality control system in place to ensure the safety and effectiveness of its products. The company's manufacturing facilities comply with the highest international standards, including Good Manufacturing Practice (GMP).
6. Sustainable practices: The company has a strong focus on sustainability and is committed to reducing its environmental impact. It has implemented various initiatives to reduce energy consumption, decrease waste production, and promote responsible sourcing.
7. Strong financial performance: Recordati has consistently shown strong financial performance, with revenue and profits increasing year on year. This highlights the company's ability to adapt and thrive in the ever-changing pharmaceutical industry.
8. Social responsibility: The company is involved in various social responsibility initiatives, including charitable donations, educational programs, and healthcare access in developing countries.
9. Strong corporate culture: Recordati values a culture of respect, integrity, and teamwork, promoting a positive work environment for its employees.
10. Innovation and growth: The company has a track record of successful innovation and growth, which is reflected in its expanding product portfolio and global reach.

The Recordati Industria Chimica e Farmaceutica SPA company's business model is primarily focused on the production, marketing, and distribution of pharmaceutical and chemical products. It operates as a global pharmaceutical company, with a strong focus on research and development, to provide innovative and high-quality products to consumers. The company utilizes a multi-channel approach, with a mix of direct and indirect distribution, to reach a wide range of customers in various geographic regions.
Recordati's business model also includes strategic partnerships and collaborations with other companies in the healthcare industry, as well as a strong emphasis on building and maintaining relationships with healthcare professionals. The company invests in both established and emerging markets to expand its global reach and increase market share.
In addition to its core pharmaceutical business, Recordati also has a significant presence in the chemicals industry, producing active pharmaceutical ingredients (APIs) for both its own products and for third-party manufacturers.
Overall, the company's business model combines a strong research and development focus with strategic partnerships, diversified product portfolio, and global market presence to drive growth and profitability.

1. Recordati Industria Chimica e Farmaceutica SPA is an Italian pharmaceutical company that was founded in Milan in 1926. It is one of the oldest and largest pharmaceutical companies in Italy.
2. The company specializes in developing and manufacturing pharmaceuticals for the treatment of cardiovascular and urological diseases, as well as rare diseases.
3. Recordati has a global presence with operations in over 100 countries and a wide portfolio of innovative pharmaceutical products.
4. The company has a strong commitment to research and development, investing a significant portion of its profits into developing new treatments for various diseases.
5. In 2019, Recordati reported revenues of over 1.4 billion euros and employed over 4,200 people worldwide.
6. The company has a strong focus on sustainability and has implemented various initiatives to reduce its environmental impact, such as using renewable energy and promoting responsible waste management.
7. Recordati has a long history of mergers and acquisitions, with notable acquisitions including Orphan Europe, an orphan drug specialist company, in 2010 and FIMEI, a pharmaceutical company focused on the treatment of gastrointestinal diseases, in 2016.
8. Recordati is listed on the MTA (Mercato Telematico Azionario) stock exchange in Italy, and it is also included in the FTSE MIB Index, which comprises the top 40 companies listed on the Italian Stock Exchange.
9. The company has received numerous awards and recognitions for its research and development efforts, including the Prix Galien for the development of an innovative treatment for Fabry disease.
10. Recordati has a strong commitment to corporate social responsibility and supports various initiatives and organizations, including the European Society for Paediatric Endocrinology and the European Men’s Health Forum.
See Company Due Diligence: